InterMune Reports Top-Line Results From Phase 2b Study of Danoprevir (RG7227/ITMN-191) in Patients with Chronic Hepatitis C

Thursday, April 15, 2010 Research News
Email Print This Page Comment
Font : A-A+

Number (%) of Patients(1) with Virologic Response (<LOD)(2)

Background therapy Pegasys/Copegus

+300 mg

q8h

(n=67)

+600 mg

q12h

(n=65)

+900 mg

q12h

(n=50)

+Placebo

(n=30)

Week 4 (RVR(3))

49 (73%)

56 (86%)

43 (86%)

2 (7%)

Week 12

(cEVR(4))

59 (88%)

58 (89%)

46 (92%)

13 (43%)

(1)  Missing data counted as non-response

(2)  Virologic Response = HCV RNA below the limit of detection (<LOD) as measured by Roche COBAS TaqMan HCV Test (<15 IU/mL)

(3)  RVR – Rapid Virologic Response

(4)  cEVR – complete Early Virologic Response



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook